{
    "nct_id": "NCT02966782",
    "official_title": "A Phase 1b Study Evaluating the Safety and Pharmacokinetics of Venetoclax as a Single-Agent and in Combination With Azacitidine in Subjects With Relapsed/Refractory Myelodysplastic Syndromes",
    "inclusion_criteria": "* Subjects who have relapsed or refractory MDS.\n* Subject enrolled in venetoclax monotherapy must have documented failure of prior therapy with a hypomethylating agent (HMA). HMA-failure is defined as:\n\n  1. Relapse after initial complete or partial response or hematological improvement after at least 4 cycles of azacitidine or at least 4 cycles of decitabine within the last 5 years, OR\n  2. Failure to achieve complete or partial response or hematological improvement after at least 4 cycles of azacitidine or at least 4 cycles of decitabine within the last 5 years\n* Subjects must have presence of < 20% bone marrow blasts per bone marrow biopsy/aspirate at screening.\n* Subject is not a candidate to undergo allogenic hematopoietic stem cell transplantation (HSCT).\n* Subject must have an Eastern Cooperative Oncology Group (ECOG) performance score of â‰¤2.\n* Subject must have adequate hematologic, renal, and hepatic function.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Subject has received prior therapy with a BH3 mimetic.\n* Subject has MDS evolving from a pre-existing myeloproliferative neoplasm (MPN).\n* Subject has MDS/MPN including chronic myelomonocytic leukemia (CMML), atypical chronic myeloid leukemia (CML), juvenile myelomonocytic leukemia (JMML) and unclassifiable MDS/MPN.\n* Subject has received allogeneic HSCT or solid organ transplantation.\n* Subject has received a live attenuated vaccine within 4 weeks prior to the first dose of study drug.\n* Subject is pregnant or breastfeeding.",
    "miscellaneous_criteria": ""
}